Construction and expression of a new fusion protein, thymosin alpha1-cBLyS, E. coli.
Shen. Qiong Q; Tian. Ruiyang R; Ma. Wenzhe W; Yuan. Qinsheng Q; Gong. Yi Y
Key Findings
- A 28 kDa fusion protein thymosin‑alpha‑1‑cBLyS was successfully created and expressed in E. coli
- The protein was purified using Ni‑NTA affinity chromatography
- The fusion retained full BLyS activity and showed slightly higher immunological action than synthetic thymosin‑alpha‑1
Practical Outcomes
- The work hints that linking thymosin‑alpha‑1 to other immune‑stimulating molecules might enhance its effects, but the product isn’t available for personal use and lacks human safety or dosing data. Biohackers should treat this as a proof‑of‑concept rather than a ready‑to‑apply protocol.
Summary
Scientists engineered a new protein that fuses thymosin‑alpha‑1 with a B‑cell growth factor, made it in bacteria, and purified it. The combined protein works at least as well as regular thymosin‑alpha‑1 and may boost immune activity a bit more, suggesting it could help with immune‑deficiency or improve vaccine responses, but it’s still a lab‑stage product.
Abstract
A fusion thymosin alpha1-soluble B lymphocyte stimulator (TM alpha1-cBLyS) gene was generated to engineer a bifunctional lymphokine, which was then over-produced in Escherichia coli. The molecular weight of the expressed fusion protein was approximately 28 kDa. After being purified by Ni-NTA affinity column, the fusion protein had full activity of BLyS with a slightly higher immunological action than synthetic TMalpha1. Because TM alpha1 regulates the cellular immune response and cBLyS amplifies the humoral response, this bifunctional lymphokine could be useful in the treatment of various immunodeficiency syndromes and serve as an immunomodulator to enhance the host's response to vaccination.
Study Information
pubmed
2005
2005-02-01T00:00:00.000Z
10.1007/s10529-004-7333-3
6
12